Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aripiprazole (Abilify) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder

Trial Profile

Aripiprazole (Abilify) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2019

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Apr 2019 Status changed from recruiting to completed.
    • 06 Sep 2018 Planned End Date changed from 1 Jun 2016 to 1 Mar 2019.
    • 06 Sep 2018 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top